The Methylamp™ One-Step DNA Modification Kit is a complete set of essential components which enables the experimenter to perform DNA methylation analysis using Epigentek's uniquely simplified and streamlined bisulfite method. The entire procedure can be completed within a mere 1 hour and 45 minutes and produces far superior results than any competitor kits. The Methylamp™ One-Step DNA Modification Kit is suitable for MS- PCR, real time MS-PCR, methylation sequencing, and pyrosequencing, as well as methylation microarray. The kit has the following advantages:
Principle & ProcedureThe Methylamp™ One-Step DNA Modification Kit contains all reagents required for bisulfite conversion on a DNA sample. DNA is denatured by heating, which allows DNA denaturation and bisulfite modification to be carried out simultaneously. In the modification process, bisulfite reagent reacts specifically with single-stranded DNA, thereby deaminating cytosine and creating a uracil residue. The unique DNA protection reagents contained in the modification buffer can prevent the chemical and thermophilic degradation of DNA in the bisulfite treatment. The non-toxic modified DNA capture buffer enables DNA to tightly bind to the column filter, thus DNA cleaning can be carried out on the column to effectively remove residual sodium bisulfite and salts. Modified DNA then can be eluted and stably stored at -20°C for up to 2 months.
Fig. 2. Comparative overview for using the Methylamp One-Step DNA Modification Kit.
Fig. 1. Schematic procedure for using the Methylamp One-Step DNA Modification Kit.
G1 (DNA Modification Powder)G2 (DNA Modification)G3 (Balance Solution)G4 (Modified DNA Capture)G5 (Modified DNA Cleaning)G6 (Modified DNA Elution)F-Spin ColumnF-Collection TubeUser Guide
Ntranos A et. al. (January 2019). Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis. Brain.
Gao XZ et. al. (December 2015). Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5‑aza‑2'‑deoxycytosine with potential therapeutic significance in Burkitt's lymphoma. Mol Med Rep.
Gabriel AS et. al. (August 2015). Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics. 10(8):717-26.
van Otterdijk SD et. al. (February 2015). Aberrations in DNA methylation are detectable during remission of acute lymphoblastic leukemia and predict patient outcome. Epigenomics. 7(1):35-45.
Gautrey HE et. al. (May 2014). DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells. FASEB J.
Collerton J et. al. (April 2014). Acquisition of aberrant DNA methylation is associated with frailty in the very old: findings from the Newcastle 85+ Study. Biogerontology.
Wu X et. al. (April 2014). Epigenetic Signature of Chronic Cerebral Hypoperfusion and Beneficial Effects of S-adenosylmethionine in Rats. Mol Neurobiol.
Tang W et. al. (March 2014). RhoBTB2 gene in breast cancer is silenced by promoter methylation. Int J Mol Med. 33(3):722-8.
Wang CX et. al. (February 2014). Aberrant DNA methylation and epigenetic inactivation of hMSH2 decrease overall survival of acute lymphoblastic leukemia patients via modulating cell cycle and apoptosis. Asian Pac J Cancer Prev. 15(1):355-62.
Li KK et. al. (July 2013). MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 23(4):413-25.
Yuasa Y et. al. (December 2012). Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is associated with gastric cancer risk. Int J Cancer. 131(11):2596-603.
Calabuig-Fariñas S et. al. (October 2012). Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production. Pathol Oncol Res. 18(4):793-802.
Gallardo A et. al. (April 2012). Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 106(8):1367-73.
Thathia SH et. al. (March 2012). Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica. 97(3):371-8.
Ferguson S et. al. (March 2011). The dual role of HLXB9 in leukemia. Pediatr Blood Cancer. 56(3):349-52.
Pang JC et. al. (November 2010). KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 20(6):1021-32.
Cheng ZD et. al. (February 2010). Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods. Chin J Cancer. 29(2):163-6.
Novara F et. al. (October 2009). Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 126(4):511-20.
Cheetham S et. al. (June 2008). SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer. 98(11):1810-9.
Otsubo T et. al. (February 2008). SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 98(4):824-31.
Treilleux I et. al. (July 2007). The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology. 51(1):63-9.